Tadalafil for the treatment of benign prostatic hyperplasia
- 22 March 2019
- journal article
- review article
- Published by Taylor & Francis in Expert Opinion on Pharmacotherapy
- Vol. 20 (8) , 929-937
Abstract
Introduction: In men, lower urinary tract symptoms (LUTS) are primarily attributed to benign prostatic hyperplasia (BPH). Therapeutic options are targeted to relax prostate smooth muscle and/or reduce prostate enlargement. Areas covered: This article reviews the major preclinical and clinical data on PDE5 inhibitors with a specific focus on tadalafil. It includes details of the role of the nitric oxide (NO)-cyclic guanosine monophosphate (cGMP) – PDE5 pathway in the LUT organs (bladder and prostate) in addition to the available data on tadalafil in patients with LUTS secondary to BPH with or without erectile dysfunction (ED). Expert opinion: Preclinical and clinical data have clearly demonstrated that PDE5 inhibitors induce bladder and prostate relaxation, which contributes to the improvement seen in storage symptoms in both animal models of bladder and prostate hypercontractility. Tadalafil is effective both as a monotherapy and add-on therapy in patients with LUTS secondary to BPH. Furthermore, as LUTS-BPH and ED are urological disorders that commonly coexist in aging men, tadalafil is more advantageous than α1-adrenoceptors and should be used as the first option. Tadalafil is a safe and tolerable therapy and unlike α1- adrenoceptors and 5-alpha reductase inhibitors, which can cause sexual dysfunctions, tadalafil improves sexual function.Keywords
This publication has 70 references indexed in Scilit:
- Identification of Amino Acid Residues Responsible for the Selectivity of Tadalafil Binding to Two Closely Related Phosphodiesterases, PDE5 and PDE6Journal of Biological Chemistry, 2012
- Tadalafil 2.5 or 5 mg Administered Once Daily for 12 Weeks in Men with Both Erectile Dysfunction and Signs and Symptoms of Benign Prostatic Hyperplasia: Results of a Randomized, Placebo-Controlled, Double-Blind StudyThe Journal of Sexual Medicine, 2012
- Restoring Soluble Guanylyl Cyclase Expression and Function Blocks the Aggressive Course of GliomaMolecular Pharmacology, 2011
- Urological aspects of the metabolic syndromeNature Reviews Urology, 2011
- The Hormone Receptor GUCY2C Suppresses Intestinal Tumor Formation by Inhibiting AKT SignalingGastroenterology, 2010
- Role of soluble guanylyl cyclase–cyclic GMP signaling in tumor cell proliferationNitric Oxide, 2010
- Compartmentation and compartment-specific regulation of PDE5 by protein kinase G allows selective cGMP-mediated regulation of platelet functionsProceedings of the National Academy of Sciences, 2008
- Vardenafil, but not sildenafil or tadalafil, has calcium‐channel blocking activity in rabbit isolated pulmonary artery and human washed plateletsBritish Journal of Pharmacology, 2008
- The standardisation of terminology of lower urinary tract function: Report from the standardisation sub‐committee of the International Continence SocietyNeurourology and Urodynamics, 2002
- Probing Domain Functions of Chimeric PDE6α′/PDE5 cGMP-PhosphodiesteraseJournal of Biological Chemistry, 1998